Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

Crohn's Disease

This page shows the latest Crohn's Disease news and features for those working in and with pharma, biotech and healthcare.

J&J and Pfizer quietly resolve Remicade biosimilar lawsuit

J&J and Pfizer quietly resolve Remicade biosimilar lawsuit

Inflectra, apart from cases where J&J’s drug had proven ineffective for patients. ... When it came the US approval covered six indications, including rheumatoid arthritis, ankylosing spondylitis, ulcerative colitis and Crohn's disease.

Latest news

  • Lilly reports positive data from its phase 3 ulcerative colitis trial Lilly reports positive data from its phase 3 ulcerative colitis trial

    Ulcerative colitis can be debilitating and unpredictable for the hundreds of thousands of people living with this chronic disease," said Caren Heller, chief scientific officer for the Crohn's &Colitis Foundation. ... Lilly is also studying mirikizumab in

  • Homesick Homesick

    susceptible are those with underlying co-morbidities like metabolic syndrome and cardiovascular disease. ... And then we have a whole ‘other’ group – patients with psoriasis, rheumatoid arthritis, Crohn’s disease, and also oncology patients.

  • AbbVie says Allergan takeover delayed by FTC verdict AbbVie says Allergan takeover delayed by FTC verdict

    position. There’s no specified timeline for that review to complete, but AbbVie says it has “entered into a timing agreement with FTC staff that would likely result” in a ... AZ licensed the drug – which is in late-stage testing for ulcerative

  • After FDA refusal, Takeda builds case for subcutaneous Entyvio After FDA refusal, Takeda builds case for subcutaneous Entyvio

    Intravenous Entyvio is already available in 60 countries. Takeda has reported updated results from a trial of its subcutaneous formulation of Entyvio in Crohn’s disease, showing activity over a year ... An enhanced clinical response rate – defined as

  • AbbVie lauds head-to-head win for Skyrizi versus Cosentyx AbbVie lauds head-to-head win for Skyrizi versus Cosentyx

    according to AbbVie outperformed its rival across all the trial’s primary and secondary outcome measures. ... It also has registration trials for Skyrizi ongoing in Crohn's disease and ulcerative colitis due to generate results next year, as well as

More from news
Approximately 20 fully matching, plus 154 partially matching documents found.

Latest Intelligence

  • Gut instincts lead Takeda to GI pipeline success Gut instincts lead Takeda to GI pipeline success

    with Crohn’s disease or ulcerative colitis is expected to rise by around 25% by 2025, according to recent studies. ... This will help physicians take much better care of patients for something that is a lifetime disease.”.

  • Case study: 4 Sites – Navigating the course ahead Case study: 4 Sites – Navigating the course ahead

    Client:SCITERION. Agency:N/A. Campaign:4 Sites: Navigating the course ahead. Timescale:N/A. Crohn’s disease – a chronic, debilitating and progressive disease – is on the increase worldwide, but remission

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    The first test of this will be Shire’s new blockbuster-in-waiting Takhzyro, which gained EMA approval in November, for the rare disease hereditary angioedema (HAE). ... Boehringer Ingelheim) for psoriatic arthritis, Crohn’s disease and other

  • Deal Watch October 2018

    Collaboration for. development. $760m. Enterome/. Takeda. EB8018 for Crohn’s disease and other gastrointestinal. ... Roche has an existing agreement with Ionis for IONIS‐HTTRx, an antisense drug for Huntington’s Disease, and the new deal is to

  • Innovation in merger control and the impact on the pharmaceutical sector Innovation in merger control and the impact on the pharmaceutical sector

    Pipeline problems. The Commission’s novel approach has its roots in pharma mergers. ... Specifically, Hospira was selling Inflectra, an infliximab biosimilar used to treat several chronic inflammatory diseases, notably the inflammation of Crohn’s

More from intelligence
Approximately 0 fully matching, plus 24 partially matching documents found.

Latest appointments

  • TiGenix appoints Dr Marie Paule Richard TiGenix appoints Dr Marie Paule Richard

    in phase III trials for complex perianal fistulas in Crohn's disease.

  • Ex J&J VP joins board of Immune Ex J&J VP joins board of Immune

    Immune will benefit from Durrant's knowledged of the iundstry gained during time in roles such as worldwide VP at Johnson &Johnson and VP, Pharmacia until its acquisition by Pfizer. ... Its lead product candidate is bertilimumab, which is in clinical

  • Former Novartis president joins Qu Biologics Former Novartis president joins Qu Biologics

    His senior industry experience will support Qu Biologics' plans to advance the development of its investigational immunotherapies for treatments such as Crohn's disease. ... Bob Pelzer's wealth of leadership experience with Novartis and DuPont will be

More from appointments
Approximately 1 fully matching, plus 2 partially matching documents found.

Latest from PMHub

  • Article:

    The disparity of patient experiences with Crohn’s Disease in Europe and Japan. ... Head of Living With, Mariel Metcalfe, discusses the market differences regarding the patient experience of those living with Crohn’s disease in the EU vs Japan, using

  • The other side of … Crohn’s disease

    The other side of … Crohn’s disease. “After visiting about seven doctors in two different countries, I am confident to say that all can align on 2–3 points at most”. ... Meet Irene. Like millions of others worldwide (and an estimated  115, 000

  • Insights from patients during the COVID-19 pandemic Insights from patients during the COVID-19 pandemic

    We carried out a survey among patients who have any one of these conditions: chronic obstructive pulmonary disorder (COPD), ulcerative colitis (UC), Crohn’s disease (CD) and idiopathic pulmonary fibrosis (IPF). ... Interestingly, patients in all

  • July 2020: diversity and inclusion in clinical trials round-up July 2020: diversity and inclusion in clinical trials round-up

    Although there’s been an increase of inflammatory bowel disease (IBD) in underrepresented populations, there are still lots of misconceptions surrounding Crohn’s and ulcerative colitis among certain ethnic groups. ... Different ethnic groups are at

  • News: Living with Ulcerative Colitis and Crohn's Disease

    Living with Ulcerative Colitis (UC) and  Crohn’s Disease (CD) are new patient syndicated reports which offer valuable insights into patient attitudes and behaviour towards their condition, treatments and unmet needs.

More from PMHub
Approximately 5 fully matching, plus 13 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Syneos Health®

Syneos Health® (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization. The Company, including a Contract Research Organization (CRO) and...

Latest intelligence

Menopause-thumbnail.png
Breaking the silence: It’s time to talk about the menopause
Using findings from our latest opinion poll, Vicki Newlove outlines why the hidden landscape of menopause may finally be starting to change....
Committing time to making meaningful connections - top 5 tips
Read the second blog of the series looking at key barriers to effective patient engagement in pharma...
News:
Senior Analytics Specialist joins Research Partnership...

Quick links